Skip to main content

Table 4 Progression-free survival by MIPI risk category and by analyzed cohort

From: Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis

Patient cohort Median PFS (95% CI), months Median OS (95% CI), months
Temsirolimus 175/75 mg Temsirolimus 175/25 mg INV therapy Temsirolimus 175/75 mg Temsirolimus 175/25 mg INV therapy
Low risk
All n = 14 n = 15 n = 22 n = 14 n = 15 n = 22
5.3 (4.2, 10.9) 6.2 (3.5, 10.9) 2.6 (2.1, 5.4) 18.0 (11.1, 22.3) 14.5 (11.0, NA) 10.5 (6.7, 16.6)
Blastoid excluded n = 14 n = 15 n = 22 n = 14 n = 15 n = 22
5.3 (4.2, 10.9) 6.2 (3.5, 10.9) 2.6 (2.1, 5.4) 18.0 (11.1, 22.3) 14.5 (11.0, NA) 10.5 (6.7, 16.6)
Missing values for MIPI excluded n = 12 n = 13 n = 16 n = 12 n = 13 n = 16
10.9 (4.2, 10.9) 6.2 (1.9, 10.9) 2.9 (2.4, 9.7) 18.0* (14.1, 22.3) 14.5 (11.0, NA) 9.5 (5.3, 16.6)
Blastoid and missing values excluded n = 12 n = 13 n = 16 n = 12 n = 13 n = 16
10.9 (4.2, 10.9) 6.2 (1.9, 10.9) 2.9 (2.4, 9.7) 18.0* (14.1, 22.3) 14.5 (11.0, NA) 9.5 (5.3, 16.6)
Intermediate risk
All n = 24 n = 18 n = 21 n = 24 n = 18 n = 21
4.3* (2.9, 9.1) 3.4 (2.6, 3.7) 1.9 (1.6, 4.0) 12.8 (8.1, NE) 8.8 (8.1, 20.6) 12.4 (5.7, 15.1)
Blastoid excluded n = 24 n = 16 n = 19 n = 24 n = 16 n = 19
4.3 (2.9, 9.1) 3.4 (1.8, 7.0) 1.9 (1.6, 4.0) 12.8 (8.1, NA) 8.8 (8.1, 20.6) 13.6 (5.7, NA)
Missing values for MIPI excluded n = 22 n = 18 n = 19 n = 22 n = 18 n = 19
4.8* (3.1, 9.1) 3.4 (2.6, 3.7) 1.9 (1.3, 4.0) 14.3 (10.0, NA) 8.8 (8.1, 20.6) 12.4 (5.7, 15.1)
Blastoid and missing values excluded n = 22 n = 16 n = 17 n = 22 n = 16 n = 17
4.8* (3.1, 9.1) 3.4 (1.8, 7.0) 1.9 (1.3, 4.6) 14.3 (10.0, NA) 8.8 (8.1, 20.6) 12.4 (5.7, NA)
High risk
All n = 16 n = 21 n = 11 n = 16 n = 21 n = 11
4.5 (1.7, 7.4) 1.9 (1.5, 3.3) 1.6 (0.7, 1.7) 5.3 (2.0, 9.9) 4.1 (2.0, 7.2) 3.5 (2.0, 4.8)
Blastoid excluded n = 16 n = 14 n = 9 n = 16 n = 14 n = 9
4.5 (1.7, 7.4) 1.9* (1.7, 5.6) 1.6 (0.9, 1.7) 5.3 (2.0, 9.9) 5.1 (3.3, 14.6) 3.7 (3.2, 20.4)
Missing values for MIPI excluded n = 16 n = 18 n = 11 n = 16 n = 18 n = 11
4.5 (1.7, 7.4) 1.9* (1.5, 3.3) 1.6 (0.7, 1.7) 5.3 (2.0, 9.9) 4.5 (3.3, 7.2) 3.5 (2.0, 4.8)
Blastoid and missing values excluded n = 16 n = 12 n = 9 n = 16 n = 12 n = 9
4.5 (1.7, 7.4) 1.9* (1.7, 5.6) 1.6 (0.9, 1.7) 5.3 (2.0, 9.9) 5.1 (3.3, 14.6) 3.7 (3.2, 20.4)
  1. * P < 0.05 versus INV.
  2. P < 0.005 versus INV.
  3. P < 0.01 versus INV.
  4. MIPI = Mantle Cell Lymphoma International Prognostic Index; PFS = progression-free survival; CI = confidence interval; OS = overall survival; INV = Investigator’s choice of therapy.